The suppression of premature termination codons and the repair of splicing mutations in CFTR

Zhou-Suckow, 2017, Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases, Cell Tissue Res, 367, 537, 10.1007/s00441-016-2562-z Pranke, 2014, Biosynthesis of cystic fibrosis transmembrane conductance regulator, Int J Biochem Cell Biol, 52, 26, 10.1016/j.biocel.2014.03.020 Kerem, 2004, Pharmacologic therapy for stop mutations: how much CFTR activity is enough?, Curr Opin Pulm Med, 10, 547, 10.1097/01.mcp.0000141247.22078.46 Ramsey, 2011, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365, 1663, 10.1056/NEJMoa1105185 Kellermayer, 2006, Translational readthrough induction of pathogenic nonsense mutations, Eur J Med Genet, 49, 445, 10.1016/j.ejmg.2006.04.003 Keeling, 2012, Suppression of premature termination codons as a therapeutic approach, Crit Rev Biochem Mol Biol, 47, 444, 10.3109/10409238.2012.694846 Shoshani, 1992, Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease, Am J Hum Genet, 50, 222 Frischmeyer, 1999, Nonsense-mediated mRNA decay in health and disease, Hum Mol Genet, 8, 1893, 10.1093/hmg/8.10.1893 Maquat, 1995, When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells, RNA, 1, 453 Maquat, 2004, Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics, Nat Rev Mol Cell Biol, 5, 89, 10.1038/nrm1310 Chang, 2007, The nonsense-mediated decay RNA surveillance pathway, Annu Rev Biochem, 76, 51, 10.1146/annurev.biochem.76.050106.093909 Mendell, 2004, Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise, Nat Genet, 36, 1073, 10.1038/ng1429 Linde, 2007, Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin, J Clin Invest, 117, 683, 10.1172/JCI28523 Linde, 2007, The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells, Eur J Hum Genet, 15, 1156, 10.1038/sj.ejhg.5201889 Tarpey, 2007, Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation, Nat Genet, 39, 1127, 10.1038/ng2100 Wang, 2011, Overexpression of the c-myc oncogene inhibits nonsense-mediated RNA decay in B lymphocytes, J Biol Chem, 286, 40038, 10.1074/jbc.M111.266361 Wang, 2011, Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis, Mol Cell Biol, 31, 3670, 10.1128/MCB.05704-11 Walter, 2011, The unfolded protein response: from stress pathway to homeostatic regulation, Science, 334, 1081, 10.1126/science.1209038 Oren, 2014, The unfolded protein response affects readthrough of premature termination codons, EMBO Mol Med, 6, 685, 10.1002/emmm.201303347 Sermet-Gaudelus, 2016, New pharmacological approaches to treat patients with cystic fibrosis with nonsense mutations, Am J Respir Crit Care Med, 194, 1042, 10.1164/rccm.201605-1021ED Wilschanski, 2003, Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations, N Engl J Med, 349, 1433, 10.1056/NEJMoa022170 Sermet-Gaudelus, 2007, In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study, BMC Med, 5, 5, 10.1186/1741-7015-5-5 Welch, 2007, PTC124 targets genetic disorders caused by nonsense mutations, Nature, 447, 87, 10.1038/nature05756 Kerem, 2008, Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial, Lancet (London, England), 372, 719, 10.1016/S0140-6736(08)61168-X Clancy, 2007, No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations, Am J Respir Cell Mol Biol, 37, 57, 10.1165/rcmb.2006-0173OC Sermet-Gaudelus, 2010, Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis, Am J Respir Crit Care Med, 182, 1262, 10.1164/rccm.201001-0137OC Roy, 2016, Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression, Proc Natl Acad Sci U S A, 113, 12508, 10.1073/pnas.1605336113 Bidou, 2004, Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment, Gene Ther, 11, 619, 10.1038/sj.gt.3302211 Hinzpeter, 2013, Alternative splicing of in-frame exon associated with premature termination codons: implications for readthrough therapies, Hum Mutat, 34, 287, 10.1002/humu.22236 Xue, 2014, Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor, Am J Respir Cell Mol Biol, 50, 805, 10.1165/rcmb.2013-0282OC Rowe, 2011, Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54, J Mol Med (Berl), 89, 1149, 10.1007/s00109-011-0787-6 Mutyam, 2016, Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations, Am J Respir Crit Care Med, 194, 1092, 10.1164/rccm.201601-0154OC Haggie, 2017, Correctors and potentiators rescue function of the truncated W1282X-cystic fibrosis transmembrane regulator (CFTR) translation product, J Biol Chem, 292, 771, 10.1074/jbc.M116.764720 Xue, 2017, Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences, Hum Mol Genet, 26, 3116, 10.1093/hmg/ddx196 Nomakuchi, 2016, Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay, Nat Biotechnol, 34, 164, 10.1038/nbt.3427 Gonzalez-Hilarion, 2012, Rescue of nonsense mutations by amlexanox in human cells, Orphanet J Rare Dis, 7, 58, 10.1186/1750-1172-7-58 Garcia-Blanco, 2004, Alternative splicing in disease and therapy, Nat Biotechnol, 22, 535, 10.1038/nbt964 Fairbrother, 2002, Predictive identification of exonic splicing enhancers in human genes, Science, 297, 1007, 10.1126/science.1073774 Cartegni, 2003, ESEfinder: a web resource to identify exonic splicing enhancers, Nucleic Acids Res, 31, 3568, 10.1093/nar/gkg616 Fairbrother, 2000, Human genomic sequences that inhibit splicing, Mol Cell Biol, 20, 6816, 10.1128/MCB.20.18.6816-6825.2000 Zhang, 2003, Sequence information for the splicing of human pre-mRNA identified by support vector machine classification, Genome Res, 13, 2637, 10.1101/gr.1679003 Black, 2003, Mechanisms of alternative pre-messenger RNA splicing, Annu Rev Biochem, 72, 291, 10.1146/annurev.biochem.72.121801.161720 Faustino, 2003, Pre-mRNA splicing and human disease, Genes Dev, 17, 419, 10.1101/gad.1048803 Cartegni, 2002, Listening to silence and understanding nonsense: exonic mutations that affect splicing, Nat Rev Genet, 3, 285, 10.1038/nrg775 Bienvenu, 1996, Analysis of alternative splicing patterns in the cystic fibrosis transmembrane conductance regulator gene using mRNA derived from lymphoblastoid cells of cystic fibrosis patients, Eur J Hum Genet, 4, 127, 10.1159/000472186 Nissim-Rafinia, 2002, Splicing regulation as a potential genetic modifier, Trends Genet, 18, 123, 10.1016/S0168-9525(01)02619-1 Pagani, 2003, New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12, Hum Mol Genet, 12, 1111, 10.1093/hmg/ddg131 Ramalho, 2002, Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis, Am J Respir Cell Mol Biol, 27, 619, 10.1165/rcmb.2001-0004OC Chiba-Falek, 1998, The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C--> T mutation, Genomics, 53, 276, 10.1006/geno.1998.5517 Chillón, 1995, Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens, N Engl J Med, 332, 1475, 10.1056/NEJM199506013322204 Rave-Harel, 1997, The molecular basis of partial penetrance of splicing mutations in cystic fibrosis, Am J Hum Genet, 60, 87 Highsmith, 1997, Identification of a splice site mutation (2789 +5 G>A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis, Hum Mutat, 9, 332, 10.1002/(SICI)1098-1004(1997)9:4<332::AID-HUMU5>3.0.CO;2-7 Nissim-Rafinia, 2004, Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation, EMBO Rep, 5, 1071, 10.1038/sj.embor.7400273 Kole, 2012, RNA therapeutics: beyond RNA interference and antisense oligonucleotides, Nat Rev Drug Discov, 11, 125, 10.1038/nrd3625 Bennett, 2010, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, Annu Rev Pharmacol Toxicol, 50, 259, 10.1146/annurev.pharmtox.010909.105654 Friedman, 1999, Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides, J Biol Chem, 274, 36193, 10.1074/jbc.274.51.36193 Igreja, 2016, Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides, Hum Mutat, 37, 209, 10.1002/humu.22931 Crosby, 2007, Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice, J Pharmacol Exp Ther, 321, 938, 10.1124/jpet.106.119214